RxDoctor Payments Data

Bunan Alnaif, MD

Obstetrics & Gynecology · Chesapeake, VANPI 1699736629

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $95,133 of the $139,339 with a category attached, or 68.3%. 56 manufacturers reported payments, led by Lupin Inc. at 32.3% of the total. Reporting peaked in 2019 at $55,023 and has fallen 85.2% since, to $8,140 in 2025. Among obstetrics & gynecology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$139,339in general payments, 2019–2025

Across 891 payments — averaging $156.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lupin Inc.$45K
  • Myovant Sciences Inc.$32K
  • Astellas Pharma US Inc$27K
  • AMAG Pharmaceuticals, Inc.$5K
  • Coloplast$5K
  • Axonics, Inc.$3K
  • plus $22K from 50 others

What the payments were for

  • Consulting fees$2,0461%
  • Speaking & faculty fees$95,13368%
  • Travel & lodging$18,78913%
  • Food & beverage$22,65816%
  • Education$6900%
  • Gifts$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,339 in reported general payments places this provider in the 95th percentile of 992 obstetrics & gynecology providers in Virginia.

See all obstetrics & gynecology providers in Virginia

Medicare billing

Part B allowed, 2024
$260,021
Medicare patients
99
Services billed
1,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron22$14,949
EstringEstradiol24$12,856
MyrbetriqMirabegron13$8,347
Estradiol60$4,111
Estradiol (Twice Weekly)Estradiol20$2,817
Terconazole47$1,244
Clindamycin Phosphate13$1,092
Oxybutynin Chloride ErOxybutynin Chloride30$885
Raloxifene Hcl18$697
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$682
ValacyclovirValacyclovir Hcl15$476
Ketoconazole14$453
Solifenacin Succinate22$398
Metronidazole18$387
Gentamicin Sulfate17$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$82$14,94922 claims
PfizerEstring$368$12,85624 claims
Astellas Pharma US IncMyrbetriq$26,790$8,34713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 992 obstetrics & gynecology providers in Virginia.

Other obstetrics & gynecology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →